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Introduction
Anemia is a common disorder in older individuals. The
prevalence of anemia increases with age to more than 20% in
people aged 85 years and over.1,2 Approximately one fifth of
older persons with anemia are considered to have anemia of
inflammation,2 previously known as anemia of chronic dis-
ease, which is commonly found in patients with infections or
inflammatory disorders, such as rheumatoid arthritis, inflam-
matory bowel disease, cancer and chronic kidney disease.3,4
Although the exact pathophysiological mechanism of this
condition is unclear, it is likely to be mediated by immune-
driven processes.3,4
Hepcidin, a 25 amino-acid peptide hormone produced by
the liver, has been hypothesized to play a crucial role in ane-
mia of inflammation.5,6 Hepcidin is the main regulator of iron
homeostasis.7 When more iron is needed for erythropoiesis,
hepcidin production is down-regulated, leading to an
increased availability of iron for red blood cell production. In
contrast, pro-inflammatory cytokines, particularly interleukin-
6, induce the production and secretion of hepcidin.8 Hepcidin
binds to the membrane protein ferroportin, an iron efflux
channel on the surface of absorptive enterocytes, macrophages
and hepatocytes, and induces its internalization and degrada-
tion in lysosomes, thereby sequestering iron in the cytoplasm
of these cells.9 As a result, plasma iron levels drop rapidly.5,6
Transgenic mice over-expressing hepcidin and mice receiv-
ing synthetic hepcidin develop mild-to-moderate microcytic,
hypochromic anemia.10-13 In humans, increased hepcidin lev-
els have also been found in diseases characterized by overt
inflammation, such as rheumatoid arthritis and sepsis.14-16 In
addition, higher hepcidin levels have been found in anemic
patients with chronic inflammation,15 chronic kidney disease
17,18 and cancer.19 Hepcidin is, therefore, considered to be the
main mediator of anemia of inflammation.3-6
Aging is often associated with a low-grade pro-inflamma-
tory state.20,21 This mild pro-inflammatory state is thought to
elicit a chronic elevation of circulating hepcidin leading to
impaired availability of plasma iron, limiting hemoglobin
synthesis and eventually causing anemia of inflammation.5,6
Whether hepcidin also plays a role in anemia in older people
from the general population is debated. In the InChianti
study, a population-based study of older subjects in Tuscany
(Italy), urinary hepcidin levels were not higher in older indi-
viduals with anemia of inflammation.22 However, hepcidin
concentrations in urine may not always accurately reflect
plasma hepcidin concentrations, since urinary hepcidin con-
centrations may also depend on glomerular filtration, tubular
re-absorption, and local production by tubular epithelial
cells.5,23 Moreover, the (pre)-analytical variation for measure-
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ments of hepcidin in urine has been found to be relatively
high.24 So far, no data are available on levels of plasma
hepcidin in older subjects with anemia in the general pop-
ulation. Recently, more reliable plasma hepcidin assays
have become available,5,25 allowing us to investigate the
relation between plasma hepcidin levels and anemia of
inflammation in older persons in the general population. 
We used data from the Leiden 85-Plus Study, a popula-
tion-based prospective study of older individuals in
Leiden, the Netherlands, to: (a) explore correlates of plas-
ma hepcidin in older people in the general population, and
(b) to investigate the role of plasma hepcidin in anemia in
old age by testing two hypotheses; (i) older people with
anemia of inflammation have higher levels of plasma hep-
cidin and (ii) older people with iron-deficiency anemia
have lower levels of plasma hepcidin.
Design and Methods
Design, setting and participants
The Leiden 85-Plus Study is a population-based prospective fol-
low-up study of 85-year-old inhabitants of Leiden, the
Netherlands. Between September 1997 and September 1999, 705
inhabitants of Leiden reached the age of 85 and were eligible and
invited to participate in the study.26 Fourteen subjects died before
enrollment in the study and 92 subjects refused to participate
(response 87%). Of the 599 participants aged 85, 47 died before
the age of 86, 39 refused further participation and 16 refused blood
sampling. For seven participants, plasma hepcidin level could not
be measured because of small sample volume. Plasma hepcidin
levels were available for 490 participants aged 86. 
Participants were visited at their place of residence for face-to-
face interviews, the assessment of functional tests and the collec-
tion of a venous blood sample. All participants gave their informed
consent. The Medical Ethical Committee of the Leiden University
Medical Center approved the study. 
Laboratory measurements
Non-fasting blood samples were drawn before 11 a.m. Plasma
samples were stored at -80°C. 
In 2010, plasma hepcidin-25 levels at age 86 were measured in
one batch by a combination of weak cation exchange chromatog-
raphy and time-of-flight mass spectrometry (TOF-MS), using a
Microflex LT matrix-enhanced laser desorption/ionisation
(MALDI) TOF-MS platform (Bruker Daltonics, Bremen,
Germany).25 An internal standard (synthetic hepcidin-24; Peptide
International Inc., Louisville, KT, USA) was used for quantifica-
tion.27 The lower limit of detection was 0.5 nM. 
Ferritin was determined in one batch using the Dual Count Solid
Phase No Boil Assay (Diagnostic Products Corp, Los Angeles, CA,
USA). Iron [colorimetric method, sensitivity 0.97 mmol/L (5.4
mg/dL) and coefficient of variation ≤4.7%] and transferrin
[immunoturbidimetric method, sensitivity 0.09 g/L (9 mg/dL), and
coefficient of variation ≤5.0%] were measured on an Architect
clinical chemistry analyzer from Abbott (Chicago, IL, USA). Total
iron binding capacity (TIBC) was calculated as follows: TIBC
(mmol/L) = transferrin (g/L) x 25.14.28 Transferrin iron saturation
(%) was defined as plasma iron divided by TIBC multiplied by
100. Low iron status was considered present when the ferritin level
was <20 mg/L for men and <15 mg/L for women, iron level was <10
mmol/L, transferrin level was >3.7 g/L, or transferrin iron saturation
was <20%.28 When a participant fulfilled one or more of the crite-
ria, he or she was considered to have a low iron status.
Hemoglobin concentration and mean corpuscular volume
(MCV) were determined on the day the blood sample was drawn
by a fully automated system (Sysmex XE-2100, TOA Medical
Electronics, Kobe, Japan). Anemia was defined according to the
World Health Organization criteria (hemoglobin level <13 g/dL for
men and hemoglobin <12 g/dL for women).29
Plasma levels of vitamin B12 and folate at age 86 were deter-
mined in one batch using the Dual Count Solid Phase No-Boil
Assay (Diagnostic Products Corp, Los Angeles, CA, USA). Vitamin
B12 deficiency was defined as plasma vitamin B12 levels lower
than 150 pmol/L; folate deficiency was defined as plasma folate
levels lower than 7.0 nmol/L.30
Plasma creatinine concentration was measured according to the
Jaffe method on the day the blood sample was drawn. A fully
automated Hitachi 747 system (Hitachi, Tokyo, Japan) was used.
We estimated creatinine clearance using the Cockcroft–Gault for-
mula.31 A creatinine clearance <30 mL/min was considered to be
low. 
C-reactive protein (CRP) and interleukin-6 levels were deter-
mined as markers of inflammation. CRP was measured with the
Hitachi 747 automated analyzer on the day the sample was drawn
(Hitachi, Tokyo, Japan). CRP levels >5 mg/L were considered to be
high. Standard enzyme-linked immunosorbent assays (ELISA)
were performed according to the manufacturer’s guidelines
(Central Laboratory of the Blood Transfusion Service, Amsterdam,
the Netherlands) to measure interleukin-6 levels. Levels of inter-
leukin-6 >10 ng/L were considered to be high.
In 2008, plasma erythropoietin levels were measured in one
batch with the use of an immunoassay (Immulite 2500, Siemens
Medical Diagnostics, Tarrytown, USA; sensitivity 1.2 IU/L, coeffi-
cient of variation <6%).
Subtypes of anemia
Participants with anemia were subdivided according to the spe-
cific subtype of anemia, using the following criteria: (i) participants
with low iron status were classified as having iron-deficiency ane-
mia; (ii) participants with either vitamin B12 deficiency or folate
deficiency were considered to have vitamin B12/folate deficiency
anemia; (iii) participants with low creatinine clearance were clas-
sified as having anemia of kidney disease; and (iv) participants
with either (a) elevated CRP levels only, or (b) elevated CRP levels
and ferritin level >300 mg/L, and iron level <10 mmol/L or transfer-
rin iron saturation <20%, were considered to have anemia of
inflammation. Participants in whom more than one of the above-
mentioned laboratory abnormalities were identified were consid-
ered to have anemia of multiple causes. As a low iron status was
hypothesized to be associated with lower plasma hepcidin levels,
and the other causes of anemia with higher hepcidin levels, sepa-
rate groups were constructed for those with multiple causes
including iron deficiency and for those with multiple causes but
normal iron status. Participants with anemia and normal iron sta-
tus, normal vitamin B12, normal folate, normal renal function, and
normal CRP were classified as having unexplained anemia.
Other clinical parameters
Information on the presence of disease (stroke, myocardial
infarction, severe cognitive impairment, diabetes mellitus,
Parkinson disease, hip fracture, arthritis, obstructive lung disease
and malignant disease) was obtained from general practitioners,
nursing home physicians, pharmacy records and laboratory find-
ings.32 Diabetes mellitus was considered present when diagnosed
by the primary care physician, when non-fasting glucose levels
were >11.0 mmol/L, or when a participant was taking anti-diabet-
ic medication. The presence of severe cognitive impairment was
based on either a diagnosis by the general practitioner or a Mini-
Mental State Examination (MMSE) score <19 points.33
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Statistical analysis
Participants with hepcidin values below the detection limit of
0.5 nM were analyzed as having a hepcidin level of 0.5 nM.
Participants were further grouped according to quartiles of plasma
hepcidin levels. Differences in characteristics between participants
in the four quartiles were tested with the c2 test (linear-linear, one
degree of freedom) for categorical variables and the Jonckheere–
Terpstra test for continuous variables. To investigate which factors
were independently associated with plasma hepcidin, we per-
formed a multiple linear regression analysis, with ferritin, iron,
CRP and erythropoietin as independent variables and hepcidin as
the dependent variable.
Differences in hematologic parameters between different sub-
types of anemia were tested with Kruskal-Wallis tests. Plasma
hepcidin levels for participants without anemia and participants
with different subtypes of anemia are displayed as medians with
corresponding interquartile ranges (IQR) and 95% confidence
intervals (CI). Differences in hepcidin levels between subjects with
the different subtypes of anemia and those without anemia were
analyzed with Mann-Whitney U tests. 
We analyzed the data with PASW 17.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Table 1 presents the characteristics of the study partici-
pants, all aged 86. In total, 160/490 (32.7%) of the study
population were male and 107/490 (21.8%) lived in a long-
term care facility. The median MMSE score was 26 (IQR
22-28). Comorbidity was present in 377/490 (76.9%) par-
ticipants. The prevalence of anemia was 23.3% (114/490).
High CRP levels (>5 mg/L) were found in 169 participants
(34.5%). 
Plasma hepcidin levels in the total study population
ranged from <0.5 nM through 18.7 nM with a median of
3.0 nM (IQR 1.8-4.9). No differences in plasma hepcidin
levels were found between men and women [median hep-
cidin 3.1 nM (IQR 1.8-5.1) versus 3.0 nM (IQR 1.8-4.8),
P=0.58].
Table 2 shows the characteristics of the study popula-
tion at the age of 86, divided according to quartiles of hep-
cidin concentration. Median hemoglobin levels were sim-
ilar in the four hepcidin quartiles (P=0.42). Plasma hep-
cidin levels correlated with body iron status, CRP levels
and levels of erythropoietin. In a multiple linear regression
analysis, ferritin (b=0.01, P<0.01), CRP (b=0.03, P<0.01)
and erythropoietin (b=-0.04, P<0.01) were independently
associated with hepcidin. Iron was not associated with
hepcidin in this multiple linear regression model (b=-0.02,
P=0.20). 
As hypothesized, hepcidin levels were significantly
lower in participants with low iron status (n=89) than in
participants with normal iron status (n=401) [median 2.0
nM (IQR 0.5-3.5) versus 3.2 nM (IQR 2.0-5.2), P<0.01].
Participants with high CRP levels (n=169) had higher hep-
cidin levels than those with normal CRP levels (n=321):
median hepcidin 3.3 nM (IQR 1.9-5.9) versus 2.9 (IQR 1.7-
4.6) (P=0.01). No difference was observed in hepcidin lev-
els between participants with high interleukin-6 levels
[(>10 ng/L) n=192, 2.9 nM (IQR 1.5-5.5)] and participants
with low interleukin-6 levels [n=295, 3.1 nM (IQR 2.0-
4.7), P=0.69]. 
No difference was observed in hepcidin levels between
participants with anemia in general (n=114) and their
counterparts without anemia (n=376), [median hepcidin
3.7 nM (IQR 1.4-6.0) versus 3.0 nM (IQR 1.8-4.7), P=0.19]. 
Table 3 shows the hematologic characteristics of the
participants according to their subtype of anemia. The
lowest hemoglobin levels were observed in those with
iron deficiency anemia [10.9 g/dL (IQR 10.1-11.8)]; partic-
ipants with unexplained anemia had a hemoglobin level of
11.7 g/dL (IQR 10.8-12.0). As expected, lower levels of fer-
ritin and iron, higher levels of transferrin and lower trans-
ferrin iron saturation were observed in those with iron
deficiency anemia. The lowest vitamin B12 levels were
found in those with vitamin B12/folate deficiency.
Creatinine clearance was lowest among individuals with
anemia of kidney disease. The highest CRP levels were
observed in subjects with anemia of inflammation and in
those with anemia with multiple causes. In addition, the
highest serum iron levels were found in subjects with
unexplained anemia. Participants with anemia of kidney
disease had the lowest erythropoietin levels. The highest
levels of erythropoietin were observed in those with iron-
deficiency anemia. The erythropoietin level in the partici-
pants with unexplained anemia was 11.1 mIU/mL (IQR
7.5-13.9).
Figure 1 presents hepcidin levels according to anemia
subtype. Higher hepcidin levels were found in participants
with anemia of inflammation [n=23, 4.7 nM (IQR 2.8-9.1),
W.P.J. den Elzen et al.
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Table 1. Characteristics of the study population at the age of 86 years.
N=490
Men 160 (32.7%)
Long-term care facility 107 (21.8%)
Mini Mental State Examination score 26 (9-30)
Comorbidity* 377 (76.9%)
Hemoglobin (g/dL) 13.0 (10.6-15.0)
Anemia (hemoglobin <13 g/dL for men and <12 g/dL for women ) 114 (23.3%)
Mean corpuscular volume (fL) 91 (84-98)
Ferritin (mg/L) 114 (19-425)
Low ferritin (<20 mg/L for men and <15 mg/L for women) 19 (4.0%)
Iron (µmol/L) 19.1 (10.0-31.6)
Low iron (<10 mmol/L) 23 (4.8%)
Transferrin (g/L) 2.7 (2.0-3.6)
High transferrin (>3.7 g/L) 18 (3.7%)
Transferrin iron saturation (%) 28 (15-49)
Low transferrin iron saturation (<20%) 76 (15.9%)
Vitamin B12 (pmol/L) 261 (132-655)
Low vitamin B12 (<150 pmol/L) 40 (8.5%)
Folate (nmol/L) 12.5 (8.0-29.7)
Low folate (<7.0 nmol/L) 1 (0.2%)
Creatinine clearance (mL/min) 43.4 (26.4-64.6)
Low creatinine clearance (<30 mL/min) 44 (9.3%)
C-reactive protein (mg/L) 3 (0-21)
High C-reactive protein  (>5 mg/L) 169 (34.5%)
Interleukin-6 (ng/L) 7 (0-1204)
High interleukin-6 (>10 ng/L) 192 (39.4%)
Erythropoietin (mIU/mL) 10.2 (5.7-21.7)
Hepcidin (nM) 3.0 (0.5-8.8)
Continuous data are presented as median (5-95%); categorical data are presented as number and
%. *including stroke, myocardial infarct, severe cognitive impairment, diabetes, Parkinson’s dis-
ease, hip fracture, arthritis, obstructive lung disease and malignancy  
P<0.01], in participants with anemia of kidney disease
[n=8, 5.4 nM (IQR 3.8-7.2), P=0.01], and in participants
with unexplained anemia [n=29, 4.2 nM (IQR 2.7-7.2),
P=0.01]. Participants with iron-deficiency anemia [based
on ferritin, iron, transferrin and transferrin iron saturation
(n=13)] had significantly lower plasma hepcidin levels [1.4
nM (IQR 0.5-2.7)] than participants without anemia
[n=376, 3.0 nM (IQR 1.8-4.7), P<0.01]. There were six sub-
jects with anemia with iron deficiency defined by the
presence of low ferritin only, irrespective of iron, transfer-
rin and transferrin iron saturation. As expected, compared
to subjects defined as having iron-deficiency anemia on
the basis of ferritin, iron, transferrin or transferrin iron sat-
uration, the median hepcidin level in these six subjects
dropped to 0.5 nM (IQR 0.5-4.0; P=0.05 versus those with-
out anemia). Lower hepcidin levels were found in partici-
pants with anemia of multiple causes including iron defi-
ciency [n=24, 1.8 nM (0.5-3.8), P=0.03]. Hepcidin levels
did not differ between participants with anemia of multi-
ple causes but normal iron status (n=11) and participants
without anemia (P=0.63). Plasma hepcidin levels did not
differ between participants with vitamin B12 deficiency
anemia or folate deficiency anemia (n=6) and participants
without anemia (P=0.83).
Discussion
In the present study conducted among older members
of the general population, we found strong correlations
between plasma hepcidin levels, and body iron status,
CRP and erythropoietin. Lower hepcidin levels were
found in the older subjects with iron-deficiency anemia
than in their peers without anemia. Higher hepcidin levels
were found in subjects with anemia of inflammation, ane-
mia of kidney disease, and unexplained anemia.
These findings concur with our hypotheses that elderly
people with iron-deficiency anemia have lower levels of
hepcidin and that older subjects with anemia of inflamma-
tion have higher levels of hepcidin. Our findings are in line
with those of studies in animals and other selected human
populations that showed strong associations between
hepcidin levels and ferritin levels and inflammatory mark-
ers.15,16,22,25,34,35 Earlier studies have also reported lower or
even undetectable hepcidin levels in iron-deficiency ane-
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Table 2. Characteristics of the study population at the age of 86 years, divided according to quartiles of hepcidin.
Quartiles of hepcidin
1 (N=119) 2 (N=133) 3 (N=115) 4 (N=123) P
Hepcidin (nM, range) 0.5-1.7 1.8-3.0 3.1-4.8 4.9-18.7
Men 39 (32.8%) 39 (29.3%) 39 (33.9%) 43 (35.0%) 0.55
Long-term care facility 25 (21.0%) 25 (18.8%) 24 (20.9%) 33 (26.8%) 0.44
Mini-Mental State examination score 27 (22-28) 27 (23-28) 25 (20-28) 26 (21-28) 0.14
Comorbidity 94 (79.0%) 101 (75.9%) 86 (74.8%) 96 (78.0%) 0.83
Hemoglobin (g/dL) 13.0 (12.2-13.8) 13.1 (12.6-13.9) 13.1 (12.2-13.8) 13.0 (11.8-13.8) 0.42
Anemia (hemoglobin <13 g/dL 31 (26.1%) 19 (14.3%) 28 (24.3%) 36 (29.3%) 0.22
for men and <12 g/dL for women )
Mean corpuscular volume (fL) 91 (88-94) 91 (89-94) 92 (89-95) 92 (89-94) 0.26
Ferritin (mg/L) 45 (23-78) 93 (67-149) 156 (106-216) 237 (148-342) <0.01
Low ferritin (<20 mg/L for men 17 (14.5%) 0 (0%) 1 (0.9%) 1 (0.8%) <0.01
and <15 mg/L for women)
Iron (µmol/L) 18.8 (14.5-23.2) 19.3 (16.0-23.3) 19.7 (15.7-24.8) 18.9 (16.5-23.3) 0.33
Low iron (<10 µmol/L) 10 (8.6%) 6 (4.6%) 3 (2.7%) 4 (3.4%) 0.05
Transferrin (g/L) 3.0 (2.6-3.4) 2.8 (2.4-3.1) 2.6 (2.4-2.9) 2.6 (2.2-2.8) <0.01
High transferrin (>3.7 g/L) 16 (3.7%) 1 (0.8%) 1 (0.9%) 0 (0%) <0.01
Transferrin iron saturation (%) 25 (19-33) 28 (24-34) 30 (23-39) 30 (25-38) <0.01
Low transferrin iron saturation (<20%) 33 (28.4%) 19 (14.5%) 14 (12.5%) 10 (8.4%) <0.01
Vitamin B12 (pmol/L) 279 (208-353) 249 (203-329) 268 (202-362) 254 (204-340) 0.84
Low vitamin B12 (<150 pmol/L) 12 (10.3%) 9 (7.1%) 10 (9.4%) 9 (7.6%) 0.62
Folate (nmol/L) 11.8 (9.7-14.0) 12.9 (10.6-16.1) 12.5 (10.1-15.5) 12.9 (10.2-17.4) 0.09
Low folate (<7.0 nmol/L) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0.65
Creatinine clearance (mL/min) 45.1 (37.7-52.2) 42.9 (37.4-48.5) 43.8 (37.8-51.1) 42.8 (34.5-51.3) 0.22
Low creatinine clearance (<30 mL/min) 9 (7.8%) 13 (10.2%) 9 (8.1%) 13 (11.2%) 0.50
C-reactive protein (mg/L) 3 (0-7) 3 (0-7) 3 (0-6) 5 (1-8) 0.05
High C-reactive protein (>5 mg/L) 37 (31.1%) 43 (32.3%) 35 (30.4%) 54 (43.9%) 0.05
Interleukin-6 (ng/L) 9 (0-33) 6 (0-31) 5 (0-11) 9 (0-39) 0.79
High interleukin-6 (>10 ng/L) 57 (47.9%) 49 (36.8%) 28 (24.8%) 58 (47.5%) 0.57
Erythropoietin (mIU/mL) 12.3 (8.6-16.9) 10.2 (7.5-12.9) 9.6 (7.5-14.0) 9.3 (7.5-12.0) <0.01
Data are presented as number (percentage) or median (IQR). P values were obtained by c2 tests (linear-by-linear, categorical variables) and Jonckheere Terpstra tests (continuous
variables).
mia.15,22,25,36 In contrast to the findings of the InChianti
study on hepcidin measured in urine,22 we are the first to
report higher hepcidin levels in older members of the gen-
eral population with anemia of inflammation, anemia of
kidney disease, and unexplained anemia. These conflict-
ing findings between the two studies may perhaps be
explained by differences in the definition of subtypes of
anemia, and iron status in particular, or by differences in
hepcidin measurements between the InChianti study and
our study, e.g. urine versus plasma, or total hepcidin versus
hepcidin-25, respectively.5
In our study, the highest hepcidin levels were found in
those participants with anemia of chronic kidney disease,
perhaps because excretion and degradation of hepcidin by
the kidney is hampered.5,17 Although in previous studies
patients with chronic kidney disease were mostly found
to have increased plasma hepcidin levels, the association
between the glomerular filtration rate and hepcidin levels
in such patients has not yet been precisely examined.5,17,18,37
As we found erythropoietin to be highest in participants
within the lowest hepcidin quartile, and vice versa, erythro-
poiesis or erythropoietin itself may inhibit hepcidin pro-
duction. Detailed studies are necessary to shed further
light on the underlying pathophysiological mechanisms. 
A combination of several age-related physiological
changes are thought to contribute to the development of
unexplained anemia, such as (subclinical) renal insufficien-
cy, stem cell aging, androgen insufficiency, low-grade
chronic inflammation, and myelodysplasia or other types
of bone marrow failure.2,38,39 Interestingly, we found higher
levels of plasma hepcidin in those participants with unex-
plained anemia. Further studies should establish the
underlying pathophysiological mechanism, as iron status,
inflammatory status and markers of erythropoiesis were
normal in these participants. It is possible that in unex-
plained anemia, bone marrow failure is associated with
lower iron utilization by the developing erythrocytes,
resulting in higher plasma iron concentrations and higher
iron stores and, consequently, with increased hepcidin
production by hepatocytes.5,40
Iron is vital for micro-organisms.41 Humans have devel-
oped several mechanisms to deprive microbes of iron dur-
ing infections.41-43 These mechanisms include an increased
production of iron-binding proteins such as lactoferrin,43
but also a systemic response by rapidly lowering plasma
iron concentrations, mediated by a cytokine-driven
increase in hepcidin.41-43 As such, hepcidin functions as the
main regulator of iron homeostasis.5-7 At supraphysiologi-
cal concentrations, hepcidin exhibits antifungal and anti-
bacterial activities44 which resemble cysteine-rich antimi-
crobial peptides defensins and protegrins.45 Hepcidin binds
to the membrane protein ferroportin, after which duode-
nal enterocytes deliver less dietary iron to extracellular
fluid, macrophages fail to release iron that is recycled from
senescent erythrocytes and hepatocytes retain stored iron,
all causing a drop in iron levels.5,6 We found strong corre-
lations between plasma hepcidin levels and body iron sta-
tus, CRP levels and erythropoietin indicating that the reg-
ulatory mechanisms that drive hepcidin production are
intact until very old age. 
The strengths of the present study are its large popula-
tion-based sample of older individuals and the state-of-
the-art measurement of plasma hepcidin levels instead of
urinary hepcidin levels.5,6,24
Hepcidin levels were measured more than 13 years after
blood collection in non-fasting blood samples. It is not yet
known whether plasma hepcidin concentrations are direct-
ly affected by the iron content of the food that was eaten
prior to the measurement. More studies need to be done
on the influence of dietary intake and the diurnal rhythm
of hepcidin. However, we found circadian differences in
serum hepcidin levels24 and, in a recent study among
healthy human volunteers, hepcidin-25 concentrations dis-
played a diurnal variation that was not influenced by food
intake.46 The stability of plasma hepcidin over longer peri-
ods is also unknown and hepcidin tends to aggregate and
Table 3. Characteristics of the study population at the age of 86 years, divided according to subtype of anemia.
Anemia subtype
Multiple causes
Vitamin B12/ Including Normal
Iron folate Kidney iron iron
No anemia deficiency deficiency disease Inflammation deficiency status Unexplained
(n=376) (n=13) (n=6) (n=8) (n=23) (n=24) (n=11) (n=29) P
Hemoglobin (g/dL) 13.4 (12.8-14.1) 10.9 (10.1-11.8) 11.8 (11.5-12.6) 11.5 (10.3-11.7) 11.5 (11.4-11.8) 11.0 (9.8-11.6) 11.4 (11.0-12.3) 11.7 (10.8-12.0) <0.01
MCV (fL) 91 (89-94) 90 (86-94) 92 (91-94) 93 (91-95) 89 (88-94) 87 (84-90) 92 (88-94) 92 (89-95) <0.01
Ferritin (mg/L) 119 (68-202) 19 (12-46) 179 (103-240) 116 (71-236) 124 (63-377) 49 (18-105) 129 (55-262) 130 (73-320) <0.01
Iron (mmol/L) 20.0 (17.3-25.0) 13.9 (8.6-18.3) 17.7 (16.1-21.6) 18.1 (13.3-19.7) 16.7 (13.8-19.1) 10.6 (8.3-13.1) 16.0 (15.7-17.8) 18.9 (16.0-22.1) <0.01
Transferrin (g/L) 2.7 (2.4-3.0) 3.3 (3.2-3.6) 2.5 (2.0-2.7) 2.3 (2.2-3.2) 2.5 (2.1-2.8) 3.0 (2.5-3.5) 2.4 (2.2-2.7) 2.5 (2.3-2.8) <0.01
Transferrin iron 30 (24-38) 18 (11-20) 29 (25-37) 24 (23-32) 25 (23-31) 16 (11-19) 27 (24-30) 29 (24-35) <0.01
saturation (%)
Vitamin B12 (pmol/L) 256 (205-338) 227 (196-332) 137 (119-480) 310 (230-380) 304 (197-388) 270 (215-339) 254 (138-344) 313 (240-504) 0.03
Folate (nmol/L) 12.7 (10.4-16.2) 12.8 (11.0-16.7) 10.9 (7.6-12.0) 13.6 (9.9-45.4) 10.4 (8.8-13.2) 11.3 (9.3-13.9) 12.7 (9.4-19.1) 12.8 (10.3-18.2) 0.02
Creatinine clearance 44.0 (38.1-51.4) 42.6 (36.2-51.3) 48.5 (41.3-60.1) 25.8 (22.1-29.0) 47.1 (37.3-57.0) 33.8 (29.4-44.5) 23.9 (19.7-29.5) 42.9 (37.3-49.9) <0.01
(mL/min)
CRP (mg/L) 3 (0-7) 2 (0-4) 2 (0-3) 2 (0-3) 10 (7-13) 12 (6-24) 12 (6-22) 1 (0-3) <0.01
Erythropoietin 9.7 (7.5-12.8) 16.2 (10.2-33.3) 11.1 (7.7-14.1) 8.2 (6.4-12.6) 13.0 (9.7-15.0) 16.4 (12.4-26.8) 8.6 (7.1-11.5) 11.1 (7.5-13.9) <0.01
(mIU/mL)
Data are presented as median (IQR). P values were obtained by Kruskal-Wallis tests. MCV: mean corpuscular volume; CRP: C-reactive protein.
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adhere to surfaces, and may even be oxidized or degrad-
ed.5,6 This may have led to measurement errors. However,
all comparisons were within the same study population,
and all samples were collected before 11 a.m., irrespective
of the subtype of anemia that the subjects had. In addition,
there is no reason to assume that iron content of the food
prior to the measurement or degradation of hepcidin was
different in subjects with different types of anemia. We,
therefore, consider it unlikely that the relative differences
presented here are due to eating habits, diurnal rhythm of
hepcidin levels or storage conditions. However, these fac-
tors may impair direct comparison with findings from
other studies using the same methodology with respect to
absolute hepcidin levels.
The median hepcidin level in our study population
(n=490), all of whom were 86 years old, was 3.0 nM (IQR
1.8-4.9). No differences were observed in hepcidin levels
between men and women. In the Nijmegen Biomedical
Study, a population-based survey in Nijmegen (the
Netherlands), serum hepcidin was measured in 2998
adults aged 18 years and over, including 16 people aged 85
years and over. The median reference level of serum hep-
cidin-25 was 4.5 nM for men, 2.0 nM for premenopausal
women, and 4.9 nM for postmenopausal women.25,34,47
The median serum hepcidin level was 6.8 nM (95% refer-
ence range 1.6-12.8) in men aged 85 years and over (n=7)
and 3.7 nM (95% reference range <0.5-15.4) in women
aged 85 years and over (n=9).34,47 The median hepcidin lev-
els observed in our population differ from those in sub-
jects aged 85 years and over in the Nijmegen Biomedical
Study, which may be explained by the small number of
persons aged 85 years and over in the Nijmegen
Biomedical Study. In order to be able to establish reference
ranges for serum hepcidin in older people in the general
population, our findings need to be confirmed in other
large studies in the same age group. 
Another limitation of this study is that the etiological
classification of anemia was not based on clinical gold
standards. Because of the epidemiological nature of this
study, the underlying causes of the anemia could not be
definitively confirmed by clinical and laboratory assess-
ments and follow-up. Our study can be considered a first
exploration of the role of plasma hepcidin in anemia in
older people in the general population. Further clinical
studies on this topic using comprehensive clinical and lab-
oratory assessments and clinical follow-up are needed. In
addition, a limitation of our study is its relatively small
sample size, especially with regards to each of the differ-
ent subtypes of anemia.
The potential clinical value of hepcidin in future diag-
nostic algorithms for anemia should also be explored, as
hepcidin levels may help to discriminate between classic
iron-deficiency anemia (low hepcidin levels) and iron defi-
ciency in the context of anemia of inflammation (high
hepcidin levels).5,6,14,48 Hepcidin levels could then be used to
predict the therapeutic response to iron administration.5,6
Future studies should also establish whether hepcidin
antagonists, e.g. anti-interleukin-6 receptor antibodies and
hepcidin-neutralizing agents,49 or targets against the hep-
cidin binding site of ferroportin, have potential value in
the treatment of anemia of inflammation in older people.6
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